Teva names new President, TAPI and Biologics Operations

pharmafile | September 12, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Novartis, Teva, appointment 

Israeli generic drug specialist Teva has announced its appointment of John Nason in a multi-faceted role as President of Teva Active Pharmaceutical Ingredients (TAPI) and the company’s biologics operations.

In his new position, Nason will oversee Teva’s vertically integrated business unit devoted to the development, manufacturing and sales of bulk active pharmaceutical ingredients (APIs) for both the company and its third-party manufacturers. He will be based at Teva’s HQ in etach Tikva, Israel.

Nason is no stranger to working at some of the biggest names in pharma, with a career that includes 12 years with Bristol-Myers Squibb, where served in a number of senior leadership positions in which he led the company’s global API organisation and third-party operations. Previous to this role, he served at Novartis, leading its bulk API manufacturing operations in his home country of Ireland, and before this he held technical transfer, engineering and project management roles at the company’s generics arm, Sandoz, in the US.

Moving from BMS in 2015, he joined Teva as Senior Vice President of European Technical Operations, a key leadership role where he held strategic and operational management responsibility – something that he will carry with him into his new role.

“John’s deep technical expertise and strong track record distinguish him as a global leader who is exceptionally qualified for this pivotal role,” commented Carlo de Notaristefani, Executive Vice President, Teva Global Operations. “I am confident in John’s ability to strengthen and grow these vital business assets for Teva and fully realise their potential to help patients and deliver for our customers around the world.”

Related Content

BMS acquires Mirati Therapeutics for $4.8bn

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …


Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

Latest content